View:
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. _____ )/1/ Hyseq, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 449163302 - -------------------------------------------------------------------------------- (CUSIP Number) January 8, 2002 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b) [X] Rule 13d-1(c) [_] Rule 13d-1(d) /1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ------------------------ -------------------------- CUSIP NO. 449163302 13G Page 1 of 4 Pages - ------------------------ -------------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSON 1. Amgen Inc. - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 2. (a) [_] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3. - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 4. Delaware - ------------------------------------------------------------------------------ SOLE VOTING POWER 5. NUMBER OF 1,491,544 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 6. OWNED BY 0 ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 7. REPORTING 1,491,544 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 8. 0 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 9. 1,491,544 - ------------------------------------------------------------------------------ CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES 10. [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 11. 7.24% (See Item 4 below) - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON 12. CO - ------------------------------------------------------------------------------ Item 1(a) Name of Issuer: Hyseq, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 670 Almanor Avenue Sunnyvale, CA 94085 Item 2(a) Name of Persons Filing: Amgen Inc. Item 2(b) Address of Principal Business Office: One Amgen Center Drive Thousand Oaks, California 91320-1799 Item 2(c) Citizenship: Delaware Item 2(d) Title of Class of Securities: Common Stock, par value $0.001 per share (the "Common Stock") Item 2(e) CUSIP Number: 449163302 Item 3. Not applicable. Item 4. Ownership. (a) Amount beneficially owned: 1,491,544 (b) Percent of class: Amgen Inc. may be deemed the beneficial owner of approximately 7.24% of the outstanding Common Stock. The calculation of the foregoing percentage and the percentage set forth in line 11 above is based on 20,599,575 shares of Common Stock outstanding, which number is calculated by adding (I) 19,108,213 (the number of shares of Common Stock shown as outstanding on the Form 10-Q Quarterly Report filed by Hyseq, Inc. with the Securities and Exchange Commission for the quarter ended September 30, 2001) and (II) 2 1,491,544 (the number of shares of Common Stock subject to a warrant to purchase Common Stock issued by Hyseq, Inc. to Amgen Inc. on January 8, 2001). (c) Number of shares to which such person has: (i) Sole power to vote or to direct the vote: 1,491,544 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 1,491,544 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. Not applicable. Item 6. Not applicable. Item 7. Not applicable. Item 8. Not applicable. Item 9. Not applicable. Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 3 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 15, 2002 AMGEN INC. By: /s/ Steve Odre ---------------------- Name: Steve Odre Title: Senior Vice President, General Counsel and Secretary